Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia
Conclusions:
Our data suggest that STATIP1 may be a negative regulator of STAT3 and demonstrate its involvement in IM therapy resistance in CML.
Source: BMC Cancer - Category: Cancer & Oncology Authors: André MencalhaStephany CorrêaDaniela SallesBárbara Du RocherMarcelo SantiagoEliana Abdelhay Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Gleevec | Leukemia | Men | Study